KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks
By Colin Kellaher
KalVista Pharmaceuticals has filed for Food and Drug Administration approval of sebetralstat, a proposed oral on-demand treatment for hereditary-angioedema attacks in people ages 12 and older.
KalVista on Tuesday said the filing is based on studies in which sebetralstat achieved the beginnings of symptom relief significantly faster than a placebo in patients with the rare genetic disease that can cause painful and debilitating attacks of tissue swelling in various parts of the body.
The Cambridge, Mass., pharmaceutical company noted that all currently approved on-demand treatment options for hereditary-angioedema attacks require either intravenous or subcutaneous administration.
KalVista said the FDA has a 60-day review period to determine whether the filing is complete and accepted for review, adding that it plans file applications with other global health authorities throughout 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 18, 2024 06:57 ET (10:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Is 16% a Good Return?
-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued